Skip to main content
. Author manuscript; available in PMC: 2024 Aug 13.
Published in final edited form as: Nat Biomed Eng. 2023 Jul 10;8(2):132–148. doi: 10.1038/s41551-023-01058-6

Extended Data Fig. 5 |. Generation of various therapeutic immune cells by MAJESTIC.

Extended Data Fig. 5 |

a, Representative flow cytometry plots of NY-ESO-1 T cells. b, Quantification of (a). c, Quantification of the CD22.CAR.iCasp T cell viability. d, Representative flow cytometry plots of CD22.CAR.iCasp9 T cells. e, Quantification of (d). f, Quantification of the CD22.CAR.iCasp9 T cells post antigen-specific cancer cells stimulation. In this figure, each assay has three technical replicates, donor 601c and donor 02 T cells were used in this figure.